CorFlow

CorFlow is developing a system that will be the first to detect and treat microvascular obstruction (MVO) in real-time.

[CorFlow @CorFlowinc]

Announcing 1st patient globally in REVITALISE trial at @EssexCTC_Cardio by @DrKeeble and team! The first study with diagnosis and therapy for #MVO in #STEMI. Humbled and privileged to be partnering with world leading cardiology experts to bring @CorFlow tech to IC's globally.

[CorFlow @CorFlowinc]

Our sleeves are pulled up and we are full speed ahead with the best team to deliver on our commitment to the cardiology community and patients. https://t.co/Be6wVFjCcy

[CorFlow @CorFlowinc]

Its CoFi time! We are absolutely thrilled to announce the FDA approval of the MOCA II IDE pivotal trial and cannot wait to get sites up and recruiting in this landmark trial for CorFlow. Want to learn more about MVO and STEMI?https://t.co/Gbdfuig9BA

[CorFlow @CorFlowinc]

Financing Round is complete. Our path to bring our unique technology for diagnosing and delivering therapies for MVO is set. Curious and want to see more?https://t.co/5LX4a1DOjD

[CorFlow @CorFlowinc]

@Hragy @mmamas1973 @ColinBerryMD @GiovanniLuigiD1 @vlgmrc @SVRaoMD Today we are thrilled to announce the close of Series B funding! Laser focussed on delivering our clinical trial programme. MVO is in our sight. Curious? Want to learn more?https://t.co/1WLfAfjrq0

[CorFlow @CorFlowinc]

Get ready for some exciting news.

[CorFlow @CorFlowinc]

The CorFlow MOCA I Trial: learnings from the first-in-human direct measurement of microvascular obstruction in STEMI via @PCRonline https://t.co/12Xiip0wVR

[CorFlow @CorFlowinc]

The MOCA I study, presented by Dr. Valgimigli at #euroPCR2023, suggests that early diagnosis & targeted treatment for high-risk patients could lead to significant advancements in the field. Read full Press Release https://t.co/YLLoUoXcQ6 @PCRonline #MVO #STEMI #unmetneed

[CorFlow @CorFlowinc]

CorFlow Announces Positive Data from the MOCA I First in Human Study Presented at EuroPCR 2023 - https://t.co/7tQW3y1iad

[CorFlow @CorFlowinc]

Experience the groundbreaking MOCA I first-in-human Late Breaking Trial presented by Dr. Marco Valgimigli at #EuroPCR Friday, May 19th. Join us in person or remotely; we invite you to be part of this significant event. #MVO #STEMI #InterventionalCardiology @PCRonline

[CorFlow @CorFlowinc]

CorFlow is thrilled to have the opportunity to participate at the #EuroPCR event and looks forward to connecting with attendees throughout the duration of the conference. #Corflow #MVO #STEMI #BeyondPCI #Unmetneed #InterventionalCardiology #Innovation #PatientsFirst #Medtech

[CorFlow @CorFlowinc]

We are Thrilled to Announce: MOCA I first in human Late Breaking Trial presented by Dr. Marco Valgimigli at #EuroPCR on Friday, May 19th. #STEMI #beyondPCI #unmetneed #interventionalcardiology #CorFlow #innovation #patientsfirst #medtech #startups

[CorFlow @CorFlowinc]

We extend our appreciation to the diligent doctors and resident physicians who make continuous efforts to protect our health every day, including on this occasion of #NationalDoctorsDay. Thank you!

[CorFlow @CorFlowinc]

Our CEO Paul Mead & co-founder Dr. Martin Rothman look forward to speaking at #LSI2023 about a unique technology addressing a major unmet need in #STEMI heart attack care & #MVO. Reach out if you would like to connect! #venturecapital #medtech #pharma #startup #cardiology

[LSI - Life Science Intelligence™ @lsintelligence]

5. CorFlow Therapeutics, Paul Mead, CEO
→ @CorFlowAG is developing a device that will diagnose microvascular obstructions (MVO) in real time during a PCI.